These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37715719)

  • 41. Dinutuximab for maintenance therapy in pediatric neuroblastoma.
    McGinty L; Kolesar J
    Am J Health Syst Pharm; 2017 Apr; 74(8):563-567. PubMed ID: 28389455
    [TBL] [Abstract][Full Text] [Related]  

  • 42. G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.
    Martinez Sanz P; van Rees DJ; van Zogchel LMJ; Klein B; Bouti P; Olsman H; Schornagel K; Kok I; Sunak A; Leeuwenburg K; Timmerman I; Dierselhuis MP; Kholosy WM; Molenaar JJ; van Bruggen R; van den Berg TK; Kuijpers TW; Matlung HL; Tytgat GAM; Franke K
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049929
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.
    Sikirica V; Haim Erder M; Xie J; Macaulay D; Diener M; Hodgkins P; Wu EQ
    Pharmacoeconomics; 2012 Aug; 30(8):e1-15. PubMed ID: 22788263
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical effectiveness and cost-effectiveness of laparoscopic surgery for colorectal cancer: systematic reviews and economic evaluation.
    Murray A; Lourenco T; de Verteuil R; Hernandez R; Fraser C; McKinley A; Krukowski Z; Vale L; Grant A
    Health Technol Assess; 2006 Nov; 10(45):1-141, iii-iv. PubMed ID: 17083853
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance.
    Barone G; Barry A; Bautista F; Brichard B; Defachelles AS; Herd F; Manzitti C; Reinhardt D; Rubio PM; Wieczorek A; van Noesel MM
    Paediatr Drugs; 2021 Nov; 23(6):537-548. PubMed ID: 34541620
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.
    Yu AL; Gilman AL; Ozkaynak MF; Naranjo A; Diccianni MB; Gan J; Hank JA; Batova A; London WB; Tenney SC; Smith M; Shulkin BL; Parisi M; Matthay KK; Cohn SL; Maris JM; Bagatell R; Park JR; Sondel PM
    Clin Cancer Res; 2021 Apr; 27(8):2179-2189. PubMed ID: 33504555
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies.
    Mora J; Castañeda A; Flores MA; Santa-María V; Garraus M; Gorostegui M; Simao M; Perez-Jaume S; Mañe S
    Front Pharmacol; 2020; 11():575009. PubMed ID: 33324208
    [No Abstract]   [Full Text] [Related]  

  • 49. Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.
    Rui M; Shi F; Shang Y; Meng R; Li H
    Adv Ther; 2020 Sep; 37(9):3761-3774. PubMed ID: 32647912
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of treatment cost for neuroblastoma to the family: a single-center cross-sectional study in China.
    Jiang C; Cai S; Duan C; Xu N; Zhou Y; Peng X; Ma X
    J Med Econ; 2020 Sep; 23(9):961-966. PubMed ID: 32568600
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China.
    Tang Y; Sang H
    Front Pharmacol; 2022; 13():1030642. PubMed ID: 36386229
    [No Abstract]   [Full Text] [Related]  

  • 52. Dinutuximab for the treatment of pediatric patients with neuroblastoma.
    Greenwood K; Foster JH
    Drugs Today (Barc); 2017 Sep; 53(9):469-476. PubMed ID: 29238760
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
    Muston D; Hettle R; Monberg M; McLaurin KK; Gao W; Swallow E; Zhang S; Kalemaj I; Signorovitch J; Moore K
    Gynecol Oncol; 2020 Nov; 159(2):491-497. PubMed ID: 32951894
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China.
    Li W; Wan L
    BMJ Open; 2023 Sep; 13(9):e074245. PubMed ID: 37751954
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States.
    Wang J; Chmielowski B; Pellissier J; Xu R; Stevinson K; Liu FX
    J Manag Care Spec Pharm; 2017 Feb; 23(2):184-194. PubMed ID: 28125365
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vericiguat for the Treatment of Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event: A Cost-Effectiveness Analysis from the Perspective of Chinese Healthcare Providers.
    Yu X; Hao Y; Zhu Z; Zhang W; Liu B; Ma M; Zhang X; Wei N; Wang J; Liu F
    Clin Drug Investig; 2023 Apr; 43(4):241-250. PubMed ID: 36929485
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis.
    Yan J; Li C; Zhang X; Cheng L; Ding R; Zhang L
    Front Public Health; 2022; 10():942800. PubMed ID: 35923949
    [TBL] [Abstract][Full Text] [Related]  

  • 59. COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada.
    Ismaila AS; Risebrough N; Li C; Corriveau D; Hawkins N; FitzGerald JM; Su Z
    Respir Med; 2014 Sep; 108(9):1292-302. PubMed ID: 25175480
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model.
    Zoine JT; Knight KA; Fleischer LC; Sutton KS; Goldsmith KC; Doering CB; Spencer HT
    Oncoimmunology; 2019; 8(8):1593804. PubMed ID: 31413905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.